




Šokové stavy a indikace k antibiotické léčbě

Martin Balik

Complex Cardiac Center, Dept. of Anaesthesia and Intensive Care
1st Medical Faculty, Charles University
Prague, Czechia, EU



Conflict of interest

- Research grants: AZV 18-06-00417 (Prospective randomized double-blind study of efficacy and safety of 1c class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock), Gilead Sciences (Immune boosting in severe Covid19)
- Research support: ESICM Stoutenbeek Award (Dutch Society of Critical Care)
- Inventor and patent holder: Lactocitrate[®], EU patent (EP2609915B1), Canadian patent (No.2799624)
- Speaker Fees: FMC, GML-Biomedica, Gilead Sciences, Bbraun, AOP Orphan
- Grant to organize educational meetings: None
- Advisory board: None

Rozhodovací algoritmus (propedeutika, 12svEKG a základní TTE)...:Hypotenze, tachy/bradykardie, oligurie, MAC, laktatémie...

1.) Obstrukční šok – ANO

NE

2.) Kardiogenní šok – ANO

NE


3.) Hypovolemický šok – ANO

NE

4.) Distribuční šok: seps^e ? - ANO
anafylaxe ?, neurogenní ?


NE

5.) Endokrinní (hypoadrenal., hypothy.,
DKA), intoxikace



Hit hard, hit first – but what...?

- Unstable patient after shock.....
- Risk of late antibiotic administration (SSC:1h, mortality +7.8%/1h of delay !)



Duration of hypotension prior to effective antimicrobial therapy: impact on survival

General side effects of antibiotics

- Elimination of the community flora during the first 48h
- Opening patients to colonisations with MDRB
- High MIC in current nosocomial bugs supports selection of MDRB
- End-organ toxicity of the reserve antibiotics
- Lack of monitoring (colimycin and its 9 active metabolites....)
- Poor attention to PK/PD – misinterpretation, changes of Vd and Cl in shock
- Lack of qualification in Intensive Medicine and uncertainty in every patient's instability leads to overuse of antibiotics (...CRP ?)





PK/PD versus MIC konkrétního mikroba

- Time-over-MIC dependent antibiotika:
 - betalaktamy
 - glykopeptidy

(cíl >50% dávk intervalu nad MIC: $\pm 4-8$ mg/l)

- AUC dependent antibiotika
 - fluochinolony
- Peak a post-atb effect
 - aminoglykosidy




Šok a změny distribuce tělesných tekutin



- Proporcionální závažnosti a trvání šoku – vzestup ECW.....
 $C = \text{dose} / V_d$ $Cl = V_d * K_e$ $T_{1/2} = \ln 2 * V_d / Cl$
- Alterace kapilární permeability - ↑ ECW/TBW a ↑ ECW/ICW
- Katabolismus a ztráta tělesného proteinu, nekrosa a apoptosa buněk – ↑ ECW/ICW
- TBW se může měnit jen málo, stejně jako tělesná hmotnost
- **Steady state nastává za 4-5 eliminačních $T_{1/2}$ antibiotika, obvykle za 48h: Dříve nemá smysl nabírat hladiny !**
- **Vankomycin – random u kont podání (ráno)**
- **Aminoglykosidy – trough před podáním (ordinujte proto 06-12....)**


Risk factors of infection in shock

- Aspiration
- Prolonged gut hypoperfusion
- Lung contusion – is this CAP ?
- TTM – hypothermia
- Periresuscitation „semi-sterile“ line insertions




Aspiration = bronchoscopy

- Reported in 28% of OHCA
- Likely more in purely paramedic-managed OHCA
- Antibiotics with impact on morbidity only if aspiration (Noc M, et al: Prophylactic versus empirical antibiotics in CPR patients, Resuscitation 2012)
- FOB 24/7 managed by intensivists as per protocol




+36h



Immediately after FOB

Pleural pathologies – is this pneumonia ?



Gut reperfusion as indication to antibiotics

Observational Study

Medicine[®]

Intensive Care Med
<https://doi.org/10.1007/s00134-022-06637-w>

The association of early resuscitation following arrest with neurological

ORIGINAL

A retrospective observation

Christoph Schriefl, MD^{a,*}, Philipp Steininger, Michael Poppe, MD^a, Florian Ettl, MD^a, Alexander Heidrun Losert, MD^a, Michael Schwameis, MD^b, Christian Schoergenhofer, MD^c


Factors associated with acute mesenteric ischemia among critically ill ventilated patients with shock: a post hoc analysis of the NUTRIREA2 trial

Gaël Piton^{1,56*}, Amélie Le Gouge^{2,3}, Julie Boisramé-Helms^{4,5}, Nadia Anguel⁶, Laurent Argaud⁷,

- Post-CPR diarrhoea (min 2x >12h post ROSC)
- Pathophysiology of NOMI – link to catecholamines and haemodynamic instability
- Multivariate odds ratio for a poor neurologic outcome 5.90, 95%CI 1.28-27, p=0.02





Reperfusion gut after OHCA



- A reperfusion swelling of the small bowel in the patient on Ecpella. Note the thickened gut wall of 9-11 mm.

Mild hypothermia as predisposing factor to VAP ?

Increased risk of ventilator-associated pneumonia in patients after cardiac arrest treated with mild therapeutic hypothermia

Julia Hasslacher¹ | Fabian Steinkohl² | Hanno Ulmer³ | Georg Lehner¹ | Sebastian Klein¹ | Timo Mayerhoefer¹  | Michael Joannidis¹ 

- 23% VAP, 6% microbiol confirmed

	All patients (n = 171)	VAP (n = 39)	No VAP (n = 132)	p-value
CRP max [mg/dl], median (IQR)	14.8 (8.6-21.7)	20.4 (14.5-27.2)	12.3 (7.6-18.9)	.0001
PCT max [µg/L], median (IQR)	2.8 (0.6-14.1)	3.3 (1.1-12.3)	2.2 (0.5-14.4)	.188
Leucocyte count max [G/L], median (IQR)	17.2 (13.1-22.9)	18.2 (14.2-23.9)	16.5 (12.8-22.8)	.171
Mild therapeutic hypothermia, n (%)	81 (47)	24 (62)	57 (43)	.044

Should we use antibiotics preventively ?

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest

B. François, A. Cariou, R. Clere-Jehl, P.-F. Dequin, F. Renon-Carron, T. Daix, C. Guitton, N. Deye, S. Legriél, G. Plantefève, J.-P. Quenot, A. Desachy, T. Kamel, S. Bedon-Cardé, J.-L. Diehl, N. Chudeau, E. Karam, I. Durand-Zaleski, B. Giraudeau, P. Vignon, and A. Le Gouge, for the CRICS-TRIGGERSEP Network and the ANTHARTIC Study Group*

- Excluded aspirated patients
- Excluded primary infections , known MDRB colonisations
- Only shockable rhythms
- **48h of potentiated ampicilin**

A Early Ventilator-Associated Pneumonia




No. at Risk	0	1	2	3	4	5	6	7
Control group	95	93	82	65	48	38	29	18
Antibiotic group	99	96	86	63	48	33	28	22

Complication

	Antibiotic Group (N=99)	Control Group (N=95)	Hazard Ratio (95% CI)	P Value
Ventilator-associated pneumonia†‡	23 (23)	37 (39)	0.55 (0.33–0.91)	
Early‡	19 (19)	32 (34)	0.53 (0.31–0.92)	0.03
Late	4 (4)	5 (5)		


B Any Ventilator-Associated Pneumonia



No. at Risk	0	7	14	21	28
Control group	95	18	2	0	0
Antibiotic group	99	22	6	1	0

	Antibiotic Group (N=99)	Control Group (N=95)	Hazard Ratio (95% CI)	P Value
Ventilator-associated pneumonia†‡	23 (23)	37 (39)	0.55 (0.33–0.91)	
Early‡	19 (19)	32 (34)	0.53 (0.31–0.92)	0.03
Late	4 (4)	5 (5)		

Antibiotics – for how long ?



Some of the available markers may help....or add to confusion....





push start : results in 17 minutes

- CRP
- PCT
- Immature granulocytes
- Presepsin
- D-dimer
- Tnl or hsTnl
- Myoglobin
- BNP or NTproBNP
- NGAL
-

Procalcitonin and CRP

- CRP - normal with high NPV
- PCT: Relationship to illness severity scores – morbidity
- PCT: Relationship to mortality
- PCT correlation with bacteraemia
(*Jones A. Infectious diseases 2007, ROC 0.84*)




Meisner M: Clin Chim Acta 2002

PCT variable cut offs for infection

- Cardiogenic shock, CPR
- Endovascular interventions
- Impact of dialysis, AKI
- Cardiac surgery
- Trauma
- Burns

Diagnosis	Cut-off (ng/ml)	Sensitivity/specificity (%)
Meningitis (bacterial/viral)	1.8	100
	0.5	100
Pneumonia (bacterial/viral)	2	63
		96
Pneumonia (bacterial/atypical germs)		–
		–
Pancreatitis (infected/sterile necrosis)	1.8	94
		90
Septic shock	1.5	100
		72



Meisner M: Clin Chim Acta 2002, Ann Lab Med 2014

Morgenthaler N: Clin Lab 2002


PCT and cardiogenic shock

Cardiogenic shock	Initially low, but increasing within 1-3 days, if vasopressor support is required	May be intermediate to high (e.g. >0.5 ng/mL to >10 ng/mL)
After prolonged resuscitation, myocardial infarction	Peak Day 1	Only In case of prolonged CPR, levels are related with prognosis after CPR. Very faint increase after myocardial infarction.



- Cardiogenic shock in STEMI and PCI with no infection
- High basal PCT with steady decrease in survivors

Picariello C. HSR proceedings in intensive care and cardiovascular anesthesia 2014

Meisner M: Clin Chim Acta 2002, Ann Lab Med 2014



Immature neutrophils




Myelocyte (indicated by arrow)

Size: 12 - 18 μ m

Nucleus: Round or oval with no nucleoli

Cytoplasm: Bluish-pink containing primary and secondary granules

Nucleus : Cytoplasm ratio 2 : 1




Metamyelocyte (indicated by arrow)

Size: 10 – 18 μ m

Nucleus: Indented or kidney-shaped

Cytoplasm: Pinkish-blue containing secondary granules

Nucleus : Cytoplasm ratio 1.5 : 1




Band Cell (indicated by arrow)

Size: 10 – 16 μ m

Nucleus: Horseshoe shaped

Cytoplasm: Light pink containing many small secondary granules

Nucleus : Cytoplasm ratio 1 : 2



Mature Neutrophil (indicated by arrow)

Size: 10 – 16 μ m


Nucleus: Definite lobes separated by a narrow filament

Cytoplasm: Light pink with many small secondary granules

Nucleus : Cytoplasm ratio 1 : 3

Immature granulocytes


- correlating with mortality, *Mare TA. Critical care 2015*
- IG+WBC similar ROC AUC as CRP+WBC, *Van der Geest PJ. Journal of Critical Care 2014.*



Nierhaus A. *BMC Immunology* 2013

	WBC	CRP	IG percentage
Cutoff value	> 12.6 $10^9/L$	>99 mg/L	>0.4%
Sensitivity	45	77	58
Specificity	93	71	80
PPV	93	85	86
NPV	45	59	48

PPV indicates positive predictive value; NPV, negative predictive value.




Mare TA. Critical Care 2015

Cite this article as: Porizka M, Volny L, Kopecky P, Kunstyr J, Waldauf P, Balik M. Immature granulocytes as a sepsis predictor in patients undergoing cardiac surgery. Interact CardioVasc Thorac Surg 2019; doi:10.1093/icvts/ivy360.

Immature granulocytes as a sepsis predictor in patients undergoing cardiac surgery[†]

Michal Porizka^{a,*}, Lukas Volny^a, Petr Kopecky^a, Jan Kunstyr^a, Petr Waldauf^b and Martin Balik^a



stody	01/06/16	Filtr na nepotvrzené výsledky	
0	ZCH-RES2	ZCH-RES2	ZCH-RES2
eumoniae			negativ.
Texty hematologie			
Laboratorní poznámka		Komentář	
Krevní obraz			
Leukocyty	16,55	30,88	24,16
Erytrocyty	3,41	4,09	4,39
Hemoglobin	97	114	124
Hematokrit	0,305	0,368	0,396
Stř. obj. erytr.	89,4	90,0	90,2
Barvivo erytr.	28,4	27,9	28,2
Stř. barev. kon.	318	310	313
Distr. křív. ery	17,3	17,2	16,6
Trombocyty	187	222	185
Stř. obj. trombo	9,6	9,4	9,4
Destičkový hematokrit	0,180	0,210	0,170
Distr. křív. tr.	9,9	9,3	8,9
Dif. stroj. relativní			
Neutrofilý	89,9	93,9	92,5
Lymfocyty	5,0	2,4	4,1
Monocyty	3,3	2,8	3,1
Eozinofily	1,6	0,6	0,1
Bazofily	0,2	0,3	0,2
Dif. stroj. absolutní			
Neutrofilý abs.	14,87	28,99	22,36
Lymfocyty abs.	0,82	0,73	0,98
Monocyty abs.	0,55	0,88	0,74
Eozinofily abs.	0,27	0,19	0,02
Bazofily abs.	0,04	0,09	0,06
Ostatní hematologie-			
Nezralé granulocyty %	0,8	1,2	1,0
Nezralé granulocyty abs.	0,14	0,36	0,25
Normoblasty strojově	0,10	0,10	0,00
Normoblasty absolutní	0,02	0,04	0,01

- automatic analyser Sysmex
 - promyelocytes,
 - metamyelocytes
 - no bands
 - normal < 0.6%

Composite endpoint IG%+PCT

Dark side of antibiotics – if administered in every shock patient...

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis



Lancet 2022; 399: 629–55


Antimicrobial Resistance Collaborators*



D Car [Antibiotic resistance](#) [+ Add to myFT](#)

Ra Ukraine infections show rising threat from antibiotic resistance

Economic and political fallout from war distracts governments from health threats



Abstract

Blood and surveillance cultures from an injured service member from Ukraine grew *Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Enterococcus faecium*, and 3 distinct *Pseudomonas aeruginosa* strains. Isolates were nonsusceptible to most antibiotics and carried an array of antibiotic resistant genes, including carbapenemases (*bla*_{IMP-1}, *bla*_{NDM-1}, *bla*_{OXA-23}, *bla*_{OXA-48}, *bla*_{OXA-72}) and 16S methyltransferases (*armA* and *rmtB4*).

Pandemic 2020-2022 and MDRB



Contents lists available at ScienceDirect

Journal of Critical Care

journal homepage: www.journals.elsevier.com/journal-of-critical-care



The threat of multidrug-resistant Gram-negative respiratory infections

Daniel Reynolds¹, Jason P. Burnham², Cristina Vaz³, Kevin Betthausen³, Scott T. Micek³ and Marin H. K...

The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox



M. Balik^{a,*}, E. Svobodova^a, M. Porizka^a, M. Maly^a, P. Brestovansky^a, L. Volny^a, T. Brozek^a, T. Bartosova^a, I. Jurisinova^a, Z. Mevaldova^a, O. Misovic^a, A. Novotny^a, J. Horejsek^a, M. Otahal^a, M. Flaksa^a, Z. Stach^a, J. Rulisek^a, P. Trachta^a, J. Kolman^a, R. Sachl^a, J. Kunstyr^a, P. Kopecky^a, S. Romaniv^a, M. Huptych^b, M. Svarc^c, G. Hodkova^c, J. Fichtl^c, F. Mlejnsky^c, T. Grus^d, J. Belohlavek^e, M. Lips^a, J. Blaha^a

Organism

Acinetobacter baumannii

Escherichia coli



microorganisms



Review

Multi-Drug Resistance Bacterial Infections in Critically Ill Patients Admitted with COVID-19

Daniela Pasero^{1,2,*}, Andrea Pasquale Cossu² and Pierpaolo Terragni^{1,2}

CR: carbapenem resistance; FQR: fluoroquinolone resistance.

deaths 5001-10000 deaths

antimicrobial resistance by pathogen-
specificity; AGR: aminoglycoside resistance;

- 29% bacterial superinfections, of these 32-50% MDRB
- Mortality linked to MDRB - not to SARS-CoV-2 mutations !...spring 2021...

Conclusion and take home message

- Antibiotics related questions in shock
 - Sepsis ?
 - Prolonged LCO/gut hypoperfusion ?
 - Post-resuscitation diarrhoea ? – implies bacteremia
 - Confirmed aspiration ? – bronchoscopy warranted
 - CA vs HA flora.....off hospital >3 months ?
 - Shock in patient on immunosuppressants ?
- Indication based on markers like PCT (> 2-2.5 ng/ml), immature granulocytes (IG%)
- Differentiate non-infection associated findings
 - lung contusion, pleural effusion
- Terminate therapy within 5-7 days
- Individualize therapy !



Děkuji za pozornost !

Complex Cardiovascular Center
1st. Medical Faculty of Charles University,
General University Hospital

U nemocnice 2; 128 08, Prague, EU

T: +420 224 962 243

F: +420 224 962 118

E: martin.balik@vfn.cz

www.karim-vfn.cz

